MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from initial
public offering of...
$275,716K
Proceeds from issuance of
series d redeemable...
$198,840K
Proceeds from exercises
of stock options
$285K
Net cash provided by
financing activities
$469,820K
Canceled cashflow
$5,021K
Increase (decrease) in
cash, cash...
$8,476K
Canceled cashflow
$461,344K
Payments of deferred
financing costs
$5,021K
Maturities of marketable
debt securities
$85,500K
Stock-based compensation
expense
$36,006K
Accrued expenses
$2,899K
Accounts payable
$1,384K
Non-cash lease expense
$866K
Depreciation
$578K
Common stock issued to
neurosolis, inc
$496K
Loss on disposal of
property and equipment
-$7K
Net cash used in
investing activities
-$323,207K
Net cash used in
operating activities
-$138,137K
Canceled cashflow
$85,500K
Canceled cashflow
$42,236K
Purchases of short-term
and long-term...
$408,234K
Net loss
-$161,152K
Purchases of property and
equipment
$473K
Prepaid expenses and
other assets
$13,103K
Deferred grant earnings
-$3,239K
Net amortization of
premiums and accretion of...
$2,102K
Operating lease
liabilities
-$777K
Back
Back
Cash Flow
source: myfinsight.com
MapLight Therapeutics, Inc. (MPLT)
MapLight Therapeutics, Inc. (MPLT)